Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus

Journal of the American College of Surgeons

Volumn 193, Issue 1, 2001, Pages 12-21

  Wong, Richard J ^a   Kim, Se Heon ^b   Joe, John K ^a   Shah, Jatin P ^a   Johnson, Paul A ^c   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Yonsei University   (South Korea)

^c Neurovir   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR REGRESSION; VIRUS CONCENTRATION; VIRUS CULTURE; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0034950470     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(01)00866-3     Document Type: Article

References (19)

1. Head and neck cancer
2. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
3. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1
4. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
5. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
6. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207)
7. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma
8. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents
9. Comparison of 2 oncolytic viruses (NV1020 and G207) as treatment for experimental mental human solid tumors
10. Conditionally replicating herpes vectors for cancer therapy
11. 134.5, a gene nonessential for growth in culture
12. Evaluation of ganciclovirmediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type I (G207) therapy of brain tumors
13. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy
14. 134.5-mutants of herpes simplex virus 1
15. 134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase
16. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (aotus trivirgatus)
17. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
18. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors
19. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer